Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

56.85
-2.0300-3.45%
Volume:2.39M
Turnover:136.81M
Market Cap:5.36B
PE:-119.32
High:59.58
Open:58.64
Low:56.23
Close:58.88
52wk High:68.73
52wk Low:22.59
Shares:94.26M
Float Shares:92.77M
Volume Ratio:1.64
T/O Rate:2.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:218.53
PE(LYR):-198.53

Loading ...

Why Travere Therapeutics (TVTX) Is Up 6.2% After New FILSPARI IgA Nephropathy Patent Protection

Simply Wall St.
·
Jun 02

A Look At Travere Therapeutics (TVTX) Valuation After New FILSPARI Patent Protection Into 2037

Simply Wall St.
·
May 29

Travere confirms Notice of Allowance from USPTO for Filspari patent application

TIPRANKS
·
May 28

Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Travere Therapeutics (TVTX)

TIPRANKS
·
May 28

Travere Therapeutics wins USPTO allowance for FILSPARI IgA nephropathy use patent application

Reuters
·
May 28

Travere Therapeutics - to Submit Issued Filspari Patent for Orange Book Listing

THOMSON REUTERS
·
May 28

Travere Therapeutics Receives Notice of Allowance From the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using Filspari® (Sparsentan) in Iga Nephropathy

THOMSON REUTERS
·
May 28

Travere Therapeutics - Patent Expected to Provide U.S. Coverage for Filspari in Iga Nephropathy Into October 2037

THOMSON REUTERS
·
May 28

Travere Therapeutics raises 2018 equity plan share reserve to 25,384,114 shares

Reuters
·
May 22

Travere Therapeutics Director Timothy Coughlin sells 3,250 shares for $141,342.50

Reuters
·
May 20

Three Companies Priced Below Estimated Value In May 2026

Simply Wall St.
·
May 19

3 Stocks Possibly Trading Below Estimated Value

Simply Wall St.
·
May 13

Travere Therapeutics grants inducement equity awards covering 48,800 shares to new hires

Reuters
·
May 13

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 13

Travere Therapeutics plans offering of $400 million convertible senior notes due 2032

Reuters
·
May 12

Travere Therapeutics Inc - Offers $475 Mln of 0.50% Convertible Senior Notes Due 2032 - SEC Filing

THOMSON REUTERS
·
May 08

BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise

Reuters
·
May 08

BUZZ-Travere Therapeutics climbs after upsized $475 mln convertible financing

Reuters
·
May 07

BRIEF-Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering To Refinance 2029 Convertible Notes

Reuters
·
May 07

Travere prices upsized USD 475 million convertible senior notes due 2032

Reuters
·
May 07